NEONAX trial: Neoadjuvant plus adjuvant or only adjuvant nab-paclitaxel plus gemcitabine for resectable pancreatic cancer, a phase II study of the AIO pancreatic cancer group (AIO-PAK-0313)—Safety interim analysis.

Waldemar Uhl,Thomas Jens Ettrich,Anke Reinacher-Schick,Hana Algül,Helmut Friess,Marko Kornmann,Alexander Koenig,Michael Ghadimi,Uwe A. Wittel,Eike Gallmeier,Kai Wille,Michael Geissler,Carl C. Schimanski,Nicole Prasnikar,Andrea Tannapfel,Lukas Perkhofer,Andreas Berger,Thomas Seufferlein

NEONAX trial: Neoadjuvant plus adjuvant or only adjuvant nab-paclitaxel plus gemcitabine for resectable pancreatic cancer, a phase II study of the AIO pancreatic cancer group (AIO-PAK-0313)—Safety interim analysis.

2019

Waldemar Uhl
Thomas Jens Ettrich
Anke Reinacher-Schick
Hana Algül
Helmut Friess
Marko Kornmann
Alexander Koenig
Michael Ghadimi
Uwe A. Wittel
Eike Gallmeier
Kai Wille
Michael Geissler
Carl C. Schimanski
Nicole Prasnikar
Andrea Tannapfel
Lukas Perkhofer
Andreas Berger
Thomas Seufferlein

4128Background: Survival in pancreatic cancer (PDAC) is still poor even after curatively intended resection. Perioperative treatment approaches improve outcome in various tumor entities. Data on pe...

Keywords:

Phases of clinical research
Pancreatic cancer
Nab-paclitaxel
Interim analysis
Adjuvant
Oncology
Pathology
Gemcitabine
Medicine
Resectable Pancreatic Cancer
Internal medicine
Perioperative

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations